CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv 2020 Aug 25;4(16):3850-3852
Date
08/17/2020Pubmed ID
32797191Pubmed Central ID
PMC7448593DOI
10.1182/bloodadvances.2020002587Scopus ID
2-s2.0-85096132028 (requires institutional sign-in at Scopus site) 40 CitationsAuthor List
Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani MAuthor
Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antigens, CD19Humans
Immunoconjugates
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse